EuroBiotech: More Articles of Note


> Protalix BioTherapeutics talked up the prospect of filing for approval of PRX-102 in Fabry disease. The Israeli biotech is continuing to enroll patients in studies of the modified version of recombinant alpha-Galactosidase-A protein but thinks it already has enough subjects for a quickie approval. Release 

> Orchard Therapeutics’ IPO haul hit $225 million (€200 million) following the partial exercise of the underwriters’ option. Statement 

> Novo Nordisk entered into a research collaboration with Embark Biotech. The Danish compatriots will work to discover treatments for obesity and metabolic disease. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Acacia Pharma re-filed for approval of Barhemsys. Statement 

> Onxeo posted phase 1 data on its DNA damage response inhibitor. The data tee Onxeo up to expand its clinical program next year. Release 

> Acesion Pharma committed to initiating a phase 2 trial of cardioversion therapy AP30663 next year. The Danish biotech outlined the plans after posting phase 1 data on the atrial fibrillation drug. Statement 

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.